Clearstead Advisors’s Amicus Therapeutics FOLD Stock Holding History

Clearstead Advisors’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-33	Closed	-$470	–	2467
2025 Q4	$470	Buy	33 +32	+3,200%	+$314	﹤0.01%	2315
2025 Q3	$8	Buy	+1	New	+$7	﹤0.01%	3053
2025 Q1	–	Sell	-1,356	Closed	-$12.8K	–	2248
2024 Q4	$12.8K	Hold	1,356	–	–	﹤0.01%	1516
2024 Q3	$14.5K	Sell	1,356 -720	-35%	-$7.84K	﹤0.01%	1508
2024 Q2	$20.6K	Buy	+2,076	New	+$21.3K	﹤0.01%	1372

Other funds holding FOLD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Clearstead Advisors's FOLD Position: Q1 2026 in Review

Clearstead Advisors sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 33 shares — an estimated $470 sold.

Clearstead Advisors first reported a position in FOLD in Q2 2024 and held it in 5 quarters. The position peaked at $20.6K in Q2 2024. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Clearstead Advisors reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
Clearstead Advisors sold 33 Amicus Therapeutics shares in Q1 2026, an estimated $470.
Clearstead Advisors first reported a position in Amicus Therapeutics in Q2 2024 and held it in 5 quarters.
Clearstead Advisors's Amicus Therapeutics position peaked at $20.6K in Q2 2024.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Clearstead Advisors's 13F filing for Q1 2026, filed 6 May 2026.